COVID-19 vaccine - Lineage Cell Therapeutics
Alternative Names: Dendritic-cell vaccine - Lineage cell Therapeutics; SARS-CoV-2 prophylactic vaccineLatest Information Update: 28 Jul 2024
At a glance
- Originator Lineage Cell Therapeutics
- Class COVID-19 vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 06 Aug 2020 Lineage Cell Therapeutics announces intention to meet with Biomedical Advanced Research and Development Authority (BARDA) in August 2020 to discuss proposal for non-dilutive support for a coronavirus vaccine candidate
- 07 Jul 2020 COVID-19 vaccine - Lineage Cell Therapeutics is available for licensing as of 07 Jul 2020